Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab
Authors:
- Andrea MatucciAMAndrea Matucci
- Francesca NenciniFNFrancesca Nencini
- Sara PratesiSPSara Pratesi
- Giulia PetroniGPGiulia Petroni
- Daniele CammelliDCDaniele Cammelli
- Renato AlteriniRARenato Alterini
- Luigi RigacciLRLuigi Rigacci
- Sergio RomagnaniSRSergio Romagnani
- Enrico MaggiEMEnrico Maggi
- 22 June 2012
- journal article
- case report
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 159 (3) , 321-326
Abstract
Rituximab (RTX) is currently used in the treatment of lymphoproliferative diseases and of several rheumatologic disorders and is a frequent cause of acute infusion reactions, usually classified as cytokine release syndrome (CRS). Some infusion reactions to RTX raise concern for immediate type I hypersensitivity, even if to date RTX-specific IgE antibodies have not been reported. To improve knowledge of the mechanisms of reactions to RTX, we investigated humoral and cellular immune responses to this drug in a patient suffering from rheumatoid arthritis who displayed two immediate infusion-related reactions. RTX-exposed tolerant patients and healthy untreated subjects were used as controls. Non-isotype-specific and IgE anti-RTX antibodies were positive in the serum samples collected from the reactive patient but not in those from the control groups. Only the reactive patient also displayed skin testing positivity with RTX. More importantly, RTX-stimulated peripheral blood mononuclear cells from the reactive patient, but not from the controls, displayed a dose-dependent proliferative response associated with a Th2 cytokine production profile. Our results show the presence of RTX-specific Th2-type cells and IgE antibodies, thus suggesting that type I hypersensitivity may be an additional mechanism to CRS in the development of RTX reactions.Keywords
This publication has 17 references indexed in Scilit:
- Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic managementCurrent Opinion in Allergy and Clinical Immunology, 2011
- Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactionsAllergy, 2010
- Infusion ReactionsClinical Journal of Oncology Nursing, 2010
- Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatmentJournal of Allergy and Clinical Immunology, 2009
- Monoclonal antibody-induced cytokine-release syndromeExpert Review of Clinical Immunology, 2009
- Immunogenicity of rituximab in patients with severe pemphigusClinical Immunology, 2009
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Monoclonal Antibody First Dose Cytokine Release Syndromes–Mechanisms and PredictionJournal of Immunotoxicology, 2008
- Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodiesRheumatology, 2007
- Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodiesJournal of Pharmaceutical and Biomedical Analysis, 2005